MRI May Define Two Distinct Migraine Phenotypes - Top-Institutions - MDSpire

MRI May Define Two Distinct Migraine Phenotypes

Patients with greater migraine burden showed widespread connectivity changes and lower cortical volume.

  • By

  • Andrea Surnit

  • May 21, 2026

  • 3 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Stanford University
    Stanford University

    Stanford, CA

    Key Differentiators

    • Neurology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Neurology

  • #3

    Trøndelag Health Study
    Trøndelag Health Study

    Trøndelag, Norway

    Key Differentiators

    • Public Health

  • #4

    QIMR Berghofer Medical Research Institute
    QIMR Berghofer Medical Research Institute

    Brisbane, QLD

    Key Differentiators

    • Medical Research

  • #5

    University Federico II
    University Federico II

    Naples, Italy

    Key Differentiators

    • Medicine

Original Source(s)

MRI May Define Two Distinct Migraine Phenotypes

  • by Andrea Surnit

  • May 21, 2026

Related Content

2026 Brain and Spine Symposium Highlights Advances Across the Neurosciences

Over two days, specialists across neurology, neurosurgery and related subspecialties came together to discuss advances in stroke care, epilepsy, movement disorders, neurodegenerative disease, neuro-oncology, brain and spine surgery, interventional pain management and emerging technologies.

  • by

  • May 21, 2026

  • 1 min
Baptist Health Foundation Presents Endowed Chair Ceremony for Aviva Abosch, M.D., Ph.D.

Aviva Abosch, M.D., Ph.D., a neurosurgeon at Baptist Health Miami Neuroscience Institute, part of Baptist Health Brain and Spine Care, was installed as the Esernia Endowed Chair in Surgical Treatment of Adult Epilepsy and Movement Disorders.

  • by

  • May 21, 2026

  • 5 min
CGRP Therapies Reduced Migraine Days

Systematic review found high-certainty evidence for several calcitonin gene–related peptide–targeted therapies